Published in Proc Natl Acad Sci U S A on March 31, 1998
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Matrix-embedded cells control osteoclast formation. Nat Med (2011) 5.77
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med (2000) 5.02
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev (1999) 3.88
Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 3.61
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol (2001) 3.53
Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med (2012) 3.46
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest (2000) 3.15
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med (1999) 3.07
Osteoclasts: what do they do and how do they do it? Am J Pathol (2007) 2.93
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med (1998) 2.68
Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A (2001) 2.56
An integration of genome-wide association study and gene expression profiling to prioritize the discovery of novel susceptibility Loci for osteoporosis-related traits. PLoS Genet (2010) 2.43
A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res (2012) 2.43
Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A (2000) 2.41
Building bone to reverse osteoporosis and repair fractures. J Clin Invest (2008) 2.40
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest (2004) 2.31
Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther (2007) 2.30
Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A (2001) 2.30
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol (2012) 2.28
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A (2001) 2.27
NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol (2007) 2.25
Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A (2000) 2.20
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20
Bone destruction in arthritis. Ann Rheum Dis (2002) 2.15
Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med (1999) 2.13
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol (2000) 2.12
Mechanisms of tooth eruption and orthodontic tooth movement. J Dent Res (2008) 2.09
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther (2013) 2.06
Disorders of bone remodeling. Annu Rev Pathol (2011) 2.05
A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med (2002) 2.04
Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A (1999) 2.04
Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol (2007) 2.02
Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol (2009) 2.01
Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol (2000) 1.99
Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med (2000) 1.93
Paget disease of bone. J Clin Invest (2005) 1.92
Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov (2012) 1.91
Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol (2006) 1.89
Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop (2006) 1.88
High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng Part A (2011) 1.87
Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci U S A (2001) 1.81
Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone (2007) 1.79
PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab (2010) 1.77
Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest (2006) 1.75
Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin. Mol Cell Biol (2011) 1.70
Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc Natl Acad Sci U S A (2013) 1.70
Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol (2006) 1.67
Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest (2000) 1.67
Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J Clin Invest (1999) 1.67
Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol (2011) 1.66
Osteoclasts and giant cells: macrophage-macrophage fusion mechanism. Int J Exp Pathol (2000) 1.66
Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood (2010) 1.66
Mechanical regulation of signaling pathways in bone. Gene (2012) 1.65
M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest (2005) 1.64
Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum (2005) 1.58
RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis. J Biol Chem (2010) 1.58
Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol (2002) 1.53
RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J (2005) 1.53
Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2. J Bone Miner Res (2008) 1.53
Cortactin has an essential and specific role in osteoclast actin assembly. Mol Biol Cell (2006) 1.52
NF-Y is essential for the recruitment of RNA polymerase II and inducible transcription of several CCAAT box-containing genes. Mol Cell Biol (2005) 1.52
Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis (2008) 1.51
Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther (2011) 1.51
Control of RANKL gene expression. Bone (2009) 1.47
Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology (2007) 1.47
Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest (2001) 1.45
Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia (2008) 1.43
Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells. BMC Complement Altern Med (2017) 1.39
Osteoprotegerin and bone mineral density in hemodialysis patients. Osteoporos Int (2006) 1.39
Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol (2009) 1.39
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol (2003) 1.38
Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood (2005) 1.38
Osteocyte control of osteoclastogenesis. Bone (2012) 1.36
Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol Cell Biol (2009) 1.36
Osteoblasts induce Ca2+ oscillation-independent NFATc1 activation during osteoclastogenesis. Proc Natl Acad Sci U S A (2008) 1.35
Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis (2002) 1.35
The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: Evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification. Proc Natl Acad Sci U S A (2002) 1.34
M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. J Clin Invest (2000) 1.33
The gene for cherubism maps to chromosome 4p16. Am J Hum Genet (1999) 1.32
Osteocyte and osteoblast apoptosis and excessive bone deposition accompany failure of collagenase cleavage of collagen. J Clin Invest (2000) 1.30
Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest (2000) 1.30
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol (2014) 1.29
Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest (2000) 1.29
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int (2012) 1.29
An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation. J Exp Med (2003) 1.29
Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res (2012) 1.29
Differentiation of monocytes into multinucleated giant bone-resorbing cells: two-step differentiation induced by nurse-like cells and cytokines. Arthritis Res (2001) 1.27
Role of DNA methylation in the regulation of the RANKL-OPG system in human bone. Epigenetics (2012) 1.26
The Interplay between the bone and the immune system. Clin Dev Immunol (2013) 1.26
Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol (2005) 1.26
The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem J (1973) 22.93
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol (1988) 12.84
Unraveling function in the TNF ligand and receptor families. Science (1994) 10.83
The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell (1994) 9.25
The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature (1990) 8.94
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med (1997) 5.72
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem (1997) 4.61
Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A (1990) 4.40
Osteoblastic cells are involved in osteoclast formation. Endocrinology (1988) 4.37
Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology (1998) 4.29
Modulation of osteoclast differentiation. Endocr Rev (1992) 4.27
Advances in bone biology: the osteoclast. Endocr Rev (1996) 3.03
The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology (1989) 2.83
Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun (1997) 2.81
Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood (1995) 2.57
Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest (1993) 2.52
Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells. Endocrinology (1991) 1.90
Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med (1991) 1.80
Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58 transgenic mouse. Proc Natl Acad Sci U S A (1993) 1.80
Preparation and characterization of a mouse osteoclast-like multinucleated cell population. J Bone Miner Res (1992) 1.71
Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology (1996) 1.55
Generation of CD1+RelB+ dendritic cells and tartrate-resistant acid phosphatase-positive osteoclast-like multinucleated giant cells from human monocytes. Blood (1996) 1.55
Modulation of osteoclast differentiation by local factors. Bone (1995) 1.47
Macrophage colony stimulating factor (M-CSF) is essential for osteoclast formation in vitro. Biochem Biophys Res Commun (1991) 1.43
New resorption assay with mouse osteoclast-like multinucleated cells formed in vitro. J Bone Miner Res (1993) 1.24
Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. Biochem Biophys Res Commun (1998) 1.14
In vitro differentiation of the murine macrophage cell line BDM-1 into osteoclast-like cells. Endocrinology (1995) 1.14
Local concentrations of macrophage colony-stimulating factor mediate osteoclastic differentiation. Am J Physiol (1995) 1.13
Cellular and molecular mechanisms in the regulation and function of osteoclasts. Vitam Horm (1991) 1.13
Cloning of an osteoblastic cell line involved in the formation of osteoclast-like cells. J Cell Physiol (1990) 1.08
Lethal effect of the anti-Fas antibody in mice. Nature (1993) 9.20
Qualitative and Quantitative Analyses of Gibberellins in Vegetative Shoots of Normal, dwarf-1, dwarf-2, dwarf-3, and dwarf-5 Seedlings of Zea mays L. Plant Physiol (1988) 8.05
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell (1994) 7.23
DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs. Genes Dev (1998) 6.96
Stages of progression in drug involvement from adolescence to adulthood: further evidence for the gateway theory. J Stud Alcohol (1992) 6.71
Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet (2001) 6.67
NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell (1999) 6.34
Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology (1990) 6.04
Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol (1994) 5.93
Convenient test for screening metallo-beta-lactamase-producing gram-negative bacteria by using thiol compounds. J Clin Microbiol (2000) 5.69
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Superconductivity at 39 K in magnesium diboride. Nature (2001) 5.20
Complete nucleotide sequence of mouse immunoglobulin mu gene and comparison with other immunoglobulin heavy chain genes. Nucleic Acids Res (1980) 5.20
Cloning and complete nucleotide sequence of mouse immunoglobulin gamma 1 chain gene. Cell (1979) 5.04
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med (2000) 5.02
Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A (1984) 4.97
Gibberellin A(3) Is Biosynthesized from Gibberellin A(20) via Gibberellin A(5) in Shoots of Zea mays L. Plant Physiol (1990) 4.71
Fas and Fas ligand: lpr and gld mutations. Immunol Today (1995) 4.69
Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet (1999) 4.56
A developmental pathway involving four phenotypically and functionally distinct subsets of CD3-CD4-CD8- triple-negative adult mouse thymocytes defined by CD44 and CD25 expression. J Immunol (1993) 4.44
Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A (1990) 4.40
Osteoblastic cells are involved in osteoclast formation. Endocrinology (1988) 4.37
Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng (1999) 4.37
Effects of walking on mortality among nonsmoking retired men. N Engl J Med (1998) 4.33
Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology (1998) 4.29
The dominant non-gibberellin-responding dwarf mutant (D8) of maize accumulates native gibberellins. Proc Natl Acad Sci U S A (1988) 4.28
Modulation of osteoclast differentiation. Endocr Rev (1992) 4.27
Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A (1981) 4.12
TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell (2000) 3.90
Cloning and sequencing of two tandem genes involved in degradation of 2,3-dihydroxybiphenyl to benzoic acid in the polychlorinated biphenyl-degrading soil bacterium Pseudomonas sp. strain KKS102. J Bacteriol (1989) 3.83
Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity (1999) 3.78
Organization of the constant-region gene family of the mouse immunoglobulin heavy chain. Cell (1982) 3.72
Rearrangement of immunoglobulin gamma 1-chain gene and mechanism for heavy-chain class switch. Proc Natl Acad Sci U S A (1980) 3.70
The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis. Nature (1999) 3.65
Immunocyte Ca2+ influx system mediated by LTRPC2. Science (2001) 3.64
TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science (1996) 3.48
Induction of IRF-3/-7 kinase and NF-kappaB in response to double-stranded RNA and virus infection: common and unique pathways. Genes Cells (2001) 3.42
Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol (1998) 3.39
From beer to crack: developmental patterns of drug involvement. Am J Public Health (1993) 3.33
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A (1993) 3.29
Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci U S A (1997) 3.26
A role for hematopoietic stem cells in promoting angiogenesis. Cell (2000) 3.25
Patterns of drug use from adolescence to young adulthood: III. Predictors of progression. Am J Public Health (1984) 3.22
In vivo and in vitro stem cell function of c-kit- and Sca-1-positive murine hematopoietic cells. Blood (1992) 3.15
Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med (2000) 3.14
Bloom's and Werner's syndrome genes suppress hyperrecombination in yeast sgs1 mutant: implication for genomic instability in human diseases. Proc Natl Acad Sci U S A (1998) 3.14
IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science (1993) 3.13
Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest (1996) 3.13
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med (1999) 3.07
Multiple DNA fragment polymorphisms associated with immunoglobulin mu chain switch-like regions in man. Proc Natl Acad Sci U S A (1983) 3.07
Cloning and sequencing of the gene encoding Toho-2, a class A beta-lactamase preferentially inhibited by tazobactam. Antimicrob Agents Chemother (1998) 3.06
Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci U S A (1984) 3.06
Essential roles of the Fas ligand in the development of hepatitis. Nat Med (1997) 3.05
The dose dependence of glucocorticoid-inducible gene expression results from changes in the number of transcriptionally active templates. EMBO J (1990) 3.04
IL-10, a novel growth cofactor for mature and immature T cells. J Immunol (1990) 3.02
Coffee, alcohol and risk of coronary heart disease among Japanese men living in Hawaii. N Engl J Med (1977) 2.98
Complete nucleotide sequence of immunoglobulin gamma2b chain gene cloned from newborn nouse DNA. Nature (1980) 2.97
Characterization of fission yeast cohesin: essential anaphase proteolysis of Rad21 phosphorylated in the S phase. Genes Dev (2000) 2.94
The consequences in young adulthood of adolescent drug involvement. An overview. Arch Gen Psychiatry (1986) 2.93
Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation (1992) 2.88
Endoscopic resection of early gastric cancer. Endoscopy (1993) 2.88
Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J (1995) 2.87
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res (1996) 2.86
Biological activity of 25-hydroxyergocalciferol in rats. J Nutr (1970) 2.85
The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology (1989) 2.83
Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron (2005) 2.82
Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun (1997) 2.81
Patterns of drug use from adolescence to young adulthood: II. Sequences of progression. Am J Public Health (1984) 2.75